Assessing the Effect of Piperacillin/Tazobactam on Hematological Parameters in Patients Admitted with Moderate or Severe Foot Infections.

Will FrySean McCaffertyCatherine GoodayIan NunneyKetan K Dhatariya

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2018)

In this relatively small cohort, pancytopenia did not occur. As such, piperacillin/tazobactam appeared to have a low risk of adverse hematological outcomes and remains the treatment of choice for severe diabetes-related foot infections.

Keyphrases

early onset
type diabetes
gram negative
cardiovascular disease
glycemic control
drug induced
high intensity
emergency department
multidrug resistant